Tuis0460 • HKG
add
Sihuan Pharmaceutical Holdings Group Ltd
Vorige sluiting
$0,59
Dagwisseling
$0,57 - $0,59
Jaarwisseling
$0,49 - $1,02
Markkapitalisasie
5,40 mjd HKD
Gemiddelde volume
12,69 m
P/V-verhouding
-
Dividend-opbrengs
3,62%
Primêre beurs
HKG
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 474,85 m | -10,04% |
Bedryfskoste | 301,93 m | -12,13% |
Netto inkomste | -16,71 m | 32,67% |
Netto winsgrens | -3,52 | 25,11% |
Wins per aandeel | — | — |
EBITDA | 56,91 m | -32,62% |
Effektiewe belastingkoers | -253,73% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 4,86 mjd | 7,86% |
Totale bates | 11,53 mjd | -2,11% |
Totale aanspreeklikheid | 6,44 mjd | -1,32% |
Totale ekwiteit | 5,09 mjd | — |
Uitstaande aandele | 9,32 mjd | — |
Prys om te bespreek | 1,26 | — |
Opbrengs op bates | 0,05% | — |
Opbrengs op kapitaal | 0,09% | — |
Kontantvloei
Netto kontantverandering
| (CNY) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -16,71 m | 32,67% |
Kontant van bedrywe | 18,23 m | 28,75% |
Kontant van beleggings | 126,63 m | 152,35% |
Kontant van finansiering | -29,16 m | 73,91% |
Netto kontantverandering | 115,70 m | 344,01% |
Beskikbare kontantvloei | -12,85 m | -53,24% |
Meer oor
Sihuan Pharmaceutical is a Chinese pharmaceutical manufacturer with headquarters in Beijing and branch office in Haikou, Hainan Province. The main company in the group is the holding company Sihuan Pharmaceutical Holdings Group Ltd, which is listed on the Hong Kong stock market.
Sihuan Pharmaceutical is collaborating with the Academy of Military Medical Science in the development of the drug JK-05, intended for the treatment of Ebola virus disease. The company has been challenged by Fujifilm Holdings Corporation, which has stated that JK-05 infringes its patent rights regarding Avigan. Wikipedia
HUB
Gestig
2001
Webwerf
Werknemers
2 648
